A Way Around

Messenger RNAs are once again capturing the attention of pharmaceutical companies as a class of drugs, writes Susan Young at MIT's Technology Review. In the past, mRNAs had garnered interest, but then had been abandoned as they can also set off an immune response.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Related Posts

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

An Australian study of personalized medicine has run into problems as it recruits patients.